Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Net Cash Flow (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Net Cash Flow for 3 consecutive years, with $12.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Net Cash Flow rose 244.17% year-over-year to $12.3 million, compared with a TTM value of $45.4 million through Dec 2024, up 244.69%, and an annual FY2024 reading of $45.4 million, up 244.69% over the prior year.
  • Net Cash Flow was $12.3 million for Q4 2024 at Oramed Pharmaceuticals, up from -$42.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $66.2 million in Q2 2024 and bottomed at -$42.7 million in Q3 2024.
  • Average Net Cash Flow over 3 years is $2.3 million, with a median of $2.6 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 481.58% in 2024, while the deepest fall reached 3263.72% in 2024.
  • Year by year, Net Cash Flow stood at $7.4 million in 2022, then plummeted by 51.46% to $3.6 million in 2023, then skyrocketed by 244.17% to $12.3 million in 2024.
  • Business Quant data shows Net Cash Flow for ORMP at $12.3 million in Q4 2024, -$42.7 million in Q3 2024, and $66.2 million in Q2 2024.